NDC 0941-0484 Dianeal Low Calcium With Dextrose

Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose

NDC Product Code 0941-0484

NDC Code: 0941-0484

Proprietary Name: Dianeal Low Calcium With Dextrose What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

NDC Code Structure

  • 0941 - Baxter Healthcare Corporation
    • 0941-0484 - Dianeal Low Calcium With Dextrose

NDC 0941-0484-01

Package Description: 5000 mL in 1 BAG

NDC Product Information

Dianeal Low Calcium With Dextrose with NDC 0941-0484 is a a human prescription drug product labeled by Baxter Healthcare Corporation. The generic name of Dianeal Low Calcium With Dextrose is sodium chloride, sodium lactate, calcium chloride, magnesium chloride and dextrose. The product's dosage form is injection, solution and is administered via intraperitoneal form.

Labeler Name: Baxter Healthcare Corporation

Dosage Form: Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Dianeal Low Calcium With Dextrose Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • DEXTROSE MONOHYDRATE 1.5 g/100mL
  • SODIUM CHLORIDE 538 mg/100mL
  • SODIUM LACTATE 448 mg/100mL
  • CALCIUM CHLORIDE 18.4 mg/100mL
  • MAGNESIUM CHLORIDE 5.08 mg/100mL

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intraperitoneal - Administration within the peritoneal cavity.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Osmotic Laxative - [EPC] (Established Pharmacologic Class)
  • Increased Large Intestinal Motility - [PE] (Physiologic Effect)
  • Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
  • Osmotic Activity - [MoA] (Mechanism of Action)
  • Blood Coagulation Factor - [EPC] (Established Pharmacologic Class)
  • Increased Coagulation Factor Activity - [PE] (Physiologic Effect)
  • Calcium - [CS]
  • Cations -
  • Divalent - [CS]
  • Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
  • Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
  • Osmotic Laxative - [EPC] (Established Pharmacologic Class)
  • Osmotic Activity - [MoA] (Mechanism of Action)
  • Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
  • Increased Large Intestinal Motility - [PE] (Physiologic Effect)
  • Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
  • Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Baxter Healthcare Corporation
Labeler Code: 0941
FDA Application Number: NDA017512 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: NDA - A product marketed under an approved New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 09-27-1978 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2020 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Dianeal Low Calcium With Dextrose Product Label Images

Dianeal Low Calcium With Dextrose Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

1 Indications And Usage

DIANEAL peritoneal dialysis solutions are indicated for patients in acute or chronic renal failure.

2.1 Basic Dosing Information

DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration.Select mode of therapy, frequency of treatment, formulation, fill volume, duration of dwell, and length of dialysis based on the patient’s clinical condition, fluid, electrolyte and specific needs.The fill volume depends on body size, usually from 2.0 to 2.5 liters per 1.73m2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD). Refer to directions accompanying ancillary equipment for CAPD and APD system preparation. Product SelectionTo avoid the risk of severe dehydration and hypovolemia and to minimize the loss of protein, it is advisable to select the peritoneal dialysis solution with the lowest level of osmolarity consistent with the fluid removal requirements for that exchange. As the patient’s body weight becomes closer to the ideal dry weight, lowering the dextrose concentration of DIANEAL solution is recommended. DIANEAL 4.25% dextrose-containing solution has the highest osmolarity of the DIANEAL solutions and using it for all exchanges may cause dehydration [see Dosage Forms and Strengths (3)].

2.2 Adding Medications

  • If the resealable rubber plug on the medication port is missing or partly removed, do not use the product if medication is to be added.To add a medication:1.Put on mask. Clean and/or disinfect hands.2.Prepare medication port site using aseptic technique.3.Using a syringe with a 1-inch long, 25- to 19-gauge needle, puncture the medication port and inject additive.4.Reposition container with container ports up and evacuate medication port by squeezing and tapping it.5.Mix solution and additive thoroughly.

2.3 Directions For Use

  • WarmingDIANEAL peritoneal dialysis solution can be warmed to 37°C (98.6°F). Only dry heat should be used. For CAPD, it is best to warm solutions within the overwrap using a heating pad. Do not immerse DIANEAL solutions in water for warming. Do not use a microwave oven to warm DIANEAL solutions.To OpenTo open, tear the overwrap down at the slit and remove the solution container. Do not use sharp objects to remove the overwrap.Product InspectionParenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use solutions that are cloudy, discolored, contain visible particulate matter, or show evidence of leakage. Some opacity of the plastic, due to moisture absorption during the sterilization process, may be observed. This does not affect the solution quality or safety and may often leave a slight amount of moisture within the overwrap. The opacity should diminish gradually.Inspect the bag connector to ensure the tip protector (pull ring or blue pull tip) is attached. Do not use if the tip protector is not attached to the connector. Inspect the DIANEAL solution for signs of leakage and check for minute leaks by squeezing the container firmly. If the container has frangible(s), inspect that they are positioned correctly and are not broken. Do not use DIANEAL solution if the frangible(s) are broken or leaks are suspected as sterility may be impaired.For DIANEAL solutions in ULTRABAG containers, inspect the tubing and drain container for presence of solution. Small droplets are acceptable, but if solution flows past the frangible prior to use, do not use and discard the units.CAPD therapy using ULTRABAG containersSelect appropriate formulation from Table 1.1.Uncoil tubing and drain bag, ensuring that the transfer set is closed. 2.Break the connector (Y-set) frangible.3.Remove the tip protector from connector of solution container. Do not reuse the solution or container once the tip protector is removed.4.Immediately attach the solution container to patient connector (transfer set). 5.Clamp solution line and then break frangible near solution bag. Hang solution container and place the drainage container below the level of the abdomen.6.Open transfer set to drain the solution from abdomen. If drainage cannot be established, contact your clinician. When drainage complete, close transfer set.7.Remove clamp from solution line and flush new solution to flow into the drainage container for 5 seconds to prime the line. Clamp drain line after flush complete.8.Open transfer set to fill. When fill complete, close transfer set.9.Disconnect ULTRABAG container from transfer set and apply MINICAP disconnect cap.10.Upon completion of therapy, discard any unused portion.APD therapy using AMBU-FLEX containers with pull rings or plastic containers with blue pull tips or pull rings Select appropriate formulation from Table 1, 2 or 3.Put on mask. Clean and/or disinfect hands. Using aseptic technique;1.Remove the tip protector from connector of solution container. Do not reuse the solution or container once the tip protector is removed.2.Immediately attach the solution container to an appropriate automated peritoneal dialysis set. 3.Continue therapy as instructed in user manual or directions accompanying tubing sets for automated peritoneal dialysis. 4.Upon completion of therapy, discard any unused portion.

3 Dosage Forms And Strengths

DIANEAL peritoneal dialysis solution is formulated with the following ionic concentrations:Table 1 - DIANEAL PD-2 and Low Calcium Peritoneal Dialysis Solution ULTRABAG Container for CAPD therapy AMBU-FLEX Container with pull ring for APD therapyIonic Concentration(mEq/L)OSMOLARITY (mOsmol/L) (calc)pHSodiumCalciumMagnesiumChlorideLactateDIANEAL PD-21.5% Dextrose3465.2(4.0 to 6.5)1323.50.59640DIANEAL PD-22.5% Dextrose3965.2(4.0 to 6.5)1323.50.59640DIANEAL PD-24.25% Dextrose4855.2(4.0 to 6.5)1323.50.59640DIANEAL Low Calcium (2.5 mEq/L)1.5% Dextrose3445.2(4.0 to 6.5)1322.50.59540DIANEAL Low Calcium (2.5 mEq/L)2.5% Dextrose3955.2(4.0 to 6.5)1322.50.59540DIANEAL Low Calcium (2.5 mEq/L) 4.25% Dextrose4835.2(4.0 to 6.5)1322.50.59540Table 2 - DIANEAL Low Calcium Peritoneal Dialysis Solution Plastic container with blue pull tip for APD therapyIonic Concentration(mEq/L)OSMOLARITY (mOsmol/L) (calc)pHSodiumCalciumMagnesiumChlorideLactateDIANEAL Low Calcium (2.5 mEq/L)1.5% Dextrose3445.0 to 6.51322.50.59540DIANEAL Low Calcium (2.5 mEq/L) 2.5% Dextrose3955.0 to 6.51322.50.59540DIANEAL Low Calcium (2.5 mEq/L) 4.25% Dextrose4835.0 to 6.51322.50.59540Table 3 - DIANEAL Low Calcium Peritoneal Dialysis Solution Plastic container with pull ring for APD therapyIonic Concentration(mEq/L)OSMOLARITY (mOsmol/L) (calc)pHSodiumCalciumMagnesiumChlorideLactateDIANEAL Low Calcium (2.5 mEq/L) 1.5% Dextrose3445.0 to 5.61322.50.59540DIANEAL Low Calcium (2.5 mEq/L) 2.5% Dextrose3955.0 to 5.61322.50.59540

4 Contraindications

DIANEAL peritoneal dialysis solutions are contraindicated in patients with severe lactic acidosis.

5.1 Peritonitis And Encapsulating Peritoneal Sclerosis

Peritonitis has been associated with DIANEAL peritoneal dialysis solution use. Following use, inspect the drained fluid for the presence of fibrin or cloudiness, which may indicate the presence of peritonitis. Improper clamping or priming sequence may result in infusion of air into the peritoneal cavity, which may result in abdominal pain and/or peritonitis. If peritonitis occurs, treat with appropriate therapy.Encapsulating Peritoneal Sclerosis (EPS), sometimes fatal, is a complication of peritoneal dialysis therapy and has been reported in patients using DIANEAL solutions.

5.2 Lactic Acidosis

Monitor patients with conditions known to increase the risk of lactic acidosis [e.g., severe hypotension or sepsis that can be associated with acute renal failure, hepatic failure, inborn errors of metabolism, and treatment with drugs such as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)] before the start of treatment and during treatment with lactate-based peritoneal dialysis solutions. Use of DIANEAL solutions in patients with severe lactic acidosis is contraindicated [see Contraindications (4)].

5.3 Overinfusion

Overinfusion of peritoneal dialysis solution volume into the peritoneal cavity may be characterized by abdominal distention, feeling of fullness and/or shortness of breath. Drain the peritoneal dialysis solution from the peritoneal cavity to treat overinfusion.

5.4 Electrolyte, Fluid, And Nutrition Imbalances

Peritoneal dialysis may affect a patient’s protein, water-soluble vitamin, potassium, bicarbonate, calcium, and magnesium levels and volume status. Monitor hematology, electrolytes, blood chemistry and fluid status periodically and take appropriate clinical action.Potassium is omitted from DIANEAL solutions because dialysis may be performed to correct hyperkalemia. In situations where there is a normal serum potassium level or hypokalemia, addition of potassium chloride (up to a concentration of 4 mEq/L) to the solution may be necessary to prevent severe hypokalemia. Monitor fluid status to avoid hyper- or hypovolemia and potentially severe consequences including congestive heart failure, volume depletion and hypovolemic shock.

5.5 Hyperglycemia

DIANEAL solutions contain dextrose and may increase the risk for hyperglycemia in patients with impaired glucose tolerance. Patients may require initiation or modification of antidiabetic therapy during treatment with DIANEAL solutions. Monitor blood glucose.

6 Adverse Reactions

The following adverse reactions are discussed elsewhere in the label:Peritonitis and Encapsulating Peritoneal Sclerosis [see Warnings and Precautions (5.1)]Electrolyte and Fluid Imbalances [see Warnings and Precautions (5.4)]

6.1 Clinical Trials Experience

There are no data available on adverse reactions from controlled clinical trials conducted to evaluate the safety of DIANEAL peritoneal dialysis solutions.

6.2 Post-Marketing Experience

The following adverse experiences have been identified during post-approval use of DIANEAL solutions or in conjunction with performing the peritoneal dialysis procedure. Because these experiences are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship during drug exposure. Most of these adverse experiences are believed to be consequences of peritoneal dialysis.INFECTIONS AND INFESTATIONS: Fungal peritonitis, Peritonitis bacterial, Catheter related infectionMETABOLISM AND NUTRITION DISORDERS: Hypovolemia, Hypervolemia, Fluid retention, Hypokalemia, Hyponatremia, Dehydration, HypochloremiaVASCULAR DISORDERS: Hypotension, HypertensionRESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS: DyspneaGASTROINTESTINAL DISORDERS: Sclerosing encapsulating peritonitis, Peritonitis, Peritoneal cloudy effluent, Vomiting, Diarrhea, Nausea, Constipation, Abdominal pain, Abdominal distension, Abdominal discomfortSKIN AND SUBCUTANEOUS DISORDERS: Stevens-Johnson syndrome, Urticaria, Rash, (including pruritic, erythematous and generalized), PruritusMUSCULOSKELETAL, CONNECTIVE TISSUE DISORDERS: Myalgia, Muscle spasms, Musculoskeletal painGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: Generalized edema, Pyrexia, Malaise, Infusion site pain, Catheter related complication

7 Drug Interactions

As with other dialysis solutions, blood concentrations of dialyzable drugs may be reduced by dialysis. Dosage adjustment of concomitant medications may be necessary. Diabetic patients may require dosage adjustments of insulin or other treatments for hyperglycemia [see Warnings and Precautions (5.5)].

8.1 Pregnancy

DIANEAL peritoneal dialysis solution is a pharmacologically inactive solution. While there are no adequate and well controlled studies in pregnant women, appropriate administration of DIANEAL solutions, with appropriate monitoring of hematology, electrolytes, blood chemistry and fluid status is not expected to cause fetal harm. Animal reproduction studies have not been conducted with DIANEAL solutions. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

8.2 Lactation

The components of DIANEAL solutions are excreted in human milk.

8.4 Pediatric Use

Safety and effectiveness have been established based on published clinical data. No adequate and well-controlled studies have been conducted with DIANEAL solutions in pediatric patients.

8.5 Geriatric Use

Safety and effectiveness have been established based on published clinical data.

10 Overdosage

There is a potential for overdose resulting in hypervolemia, hypovolemia, electrolyte disturbances or hyperglycemia. Excessive use of DIANEAL peritoneal dialysis solution with 4.25% dextrose during a peritoneal dialysis treatment can result in significant removal of water from the patient.

11 Description

DIANEAL peritoneal dialysis solutions are sterile, nonpyrogenic solutions in flexible containers for intraperitoneal administration only. The peritoneal dialysis solutions contain no bacteriostatic or antimicrobial agents.DIANEAL solutions are hyperosmolar solutions.Table 4 - DIANEAL PD-2 and Low Calcium Peritoneal Dialysis Solution ULTRABAG Container for CAPD therapy AMBU-FLEX Container with pull ring for APD therapyComposition/100 mL*Dextrose, Hydrous, USPSodium Chloride, USP (NaCl)Sodium Lactate (C3H5NaO3)Calcium Chloride, USP (CaCl2•2H2O)Magnesium Chloride, USP (MgCl2•6H2O)DIANEAL PD-21.5% Dextrose1.5 g538 mg448 mg25.7 mg5.08 mgDIANEAL PD-22.5% Dextrose2.5 g538 mg448 mg25.7 mg5.08 mgDIANEAL PD-24.25% Dextrose4.25 g538 mg448 mg25.7 mg5.08 mgDIANEAL Low Calcium (2.5 mEq/L)1.5% Dextrose1.5 g538 mg448 mg18.3 mg5.08 mgDIANEAL Low Calcium (2.5 mEq/L)2.5% Dextrose2.5 g538 mg448 mg18.3 mg5.08 mgDIANEAL Low Calcium (2.5 mEq/L) 4.25% Dextrose4.25 g538 mg448 mg18.3 mg5.08 mgTable 5 - DIANEAL Low Calcium Peritoneal Dialysis Solution Plastic container with blue pull tip for APD therapyComposition/100 mL*Dextrose, HydrousSodium Chloride (NaCl)Sodium Lactate (C3H5NaO3)Calcium Chloride (CaCl2•2H2O)Magnesium Chloride (MgCl2•6H2O)DIANEAL Low Calcium (2.5 mEq/L) 1.5% Dextrose1.5 g538 mg448 mg18.4 mg5.08 mgDIANEAL Low Calcium (2.5 mEq/L) 2.5% Dextrose2.5 g538 mg448 mg18.4 mg5.08 mgDIANEAL Low Calcium (2.5 mEq/L) 4.25% Dextrose4.25 g538 mg448 mg18.4 mg5.08 mgTable 6 -DIANEAL Low Calcium Peritoneal Dialysis Solution Plastic container with pull ring for APD therapyComposition/100 mL*Dextrose, Hydrous, USPSodium Chloride, USP (NaCl)Sodium Lactate (C3H5NaO3)Calcium Chloride, USP (CaCl2•2H2O)Magnesium Chloride, USP (MgCl2•6H2O)DIANEAL Low Calcium (2.5 mEq/L) 1.5% Dextrose1.5 g538 mg448 mg18.3 mg5.08 mgDIANEAL Low Calcium (2.5 mEq/L) 2.5% Dextrose2.5 g538 mg448 mg18.3 mg5.08 mgThe plastic container is fabricated from polyvinyl chloride (PVC Plastic). Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. The amount of water that can permeate from inside the solution container into the overwrap is insufficient to affect the solution significantly.Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g. di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million; however, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by cell culture toxicity studies.

12.1 Mechanism Of Action

DIANEAL peritoneal dialysis solutions are a pharmacologically inactive, hypertonic peritoneal dialysis solution containing dextrose, a monosaccharide, as the primary osmotic agent. An osmotic gradient must be created between the peritoneal membrane and the dialysis solution in order for ultrafiltration to occur. The hypertonic concentration of glucose in DIANEAL solutions exert an osmotic pressure across the peritoneal membrane resulting in transcapillary ultrafiltration. Like other peritoneal dialysis solutions, DIANEAL solutions contain electrolytes to facilitate the correction of electrolyte abnormalities. DIANEAL solutions contain a buffer, lactate, to help normalize acid-base abnormalities.

12.3 Pharmacokinetics

AbsorptionGlucose is rapidly absorbed from the peritoneal cavity by diffusion and appears quickly in the circulation due to the high glucose concentration gradient between DIANEAL solutions compared to blood capillary glucose level. Absorption per unit time will be the highest at the start of an exchange and decreases over time. The rate of glucose absorption will be dependent upon the transport characteristics of the patient’s peritoneal membrane as determined by a peritoneal equilibration test (PET). Glucose absorption will also depend upon the concentration of glucose used for the exchange and the length of the dwell. Transport of other molecules will be dependent upon the molecular size of the solute, the concentration gradient, and the effective peritoneal surface area as determined by the PET.Metabolism and EliminationGlucose is metabolized by normal cellular pathways (i.e., glycolysis). Metabolism of lactate occurs in the liver and results in the generation of the bicarbonate. Glucose not absorbed during PD exchange procedure is removed by drainage of the PD solution from the peritoneal cavity.Drug Interaction StudiesHeparinNo human drug interaction studies with heparin were conducted. In vitro studies demonstrated no evidence of incompatibility of heparin with DIANEAL solutions.AntibioticsNo formal clinical drug interaction studies have been performed. In vitro studies of the following medications have demonstrated stability with DIANEAL solutions: amphotericin B, ampicillin, cefazolin, cefepime, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, clindamycin, deferoxamine, erythromycin, gentamicin, linezolid, mezlocillin, miconazole, moxifloxacin, nafcillin, ofloxacin, penicillin G, piperacillin, sulfamethoxazole/trimethoprim, ticarcillin, tobramycin, and vancomycin. However, aminoglycosides should not be mixed with penicillins due to chemical incompatibility.

16 How Supplied/Storage And Handling

DIANEAL peritoneal dialysis solutions are available in the following single-dose containers and fill volumes as shown in Tables 7-8:Table 7 - DIANEAL Peritoneal Dialysis Solutions for CAPD therapyContainerFill Volume (mL)Container Size (mL)Product CodeNDCULTRABAGContainerDIANEAL PD-2 Peritoneal Dialysis Solution with 1.5% Dextrose2000250030002000300050005B98665B98685B98570941-0426-520941-0426-530941-0426-55DIANEAL PD-2 Peritoneal Dialysis Solution with 2.5% Dextrose2000250030002000300050005B98765B98785B98580941-0427-520941-0427-530941-0427-55DIANEAL PD-2 Peritoneal Dialysis Solution with 4.25% Dextrose2000250030002000300050005B98965B98985B98590941-0429-520941-0429-530941-0429-55DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose150020002500300020002000300050005B97655B97665B97685B97570941-0424-510941-0424-520941-0424-530941-0424-55DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose150020002500300020002000300050005B97755B97765B97785B97580941-0430-510941-0430-520941-0430-530941-0430-55DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 4.25% Dextrose150020002500300020002000300050005B97955B97965B97985B97590941-0433-510941-0433-520941-0433-530941-0433-55Table 8 - DIANEAL Peritoneal Dialysis Solutions for APD therapyContainerFill Volume (mL)Container Size (mL)Product CodeNDCAMBU-FLEX Container with pull ringDIANEAL PD-2 Peritoneal Dialysis Solution with 1.5% Dextrose1000200030005000600010003000300060006000L5B5163L5B5166L5B5169L5B5193L5B97100941-0411-050941-0411-060941-0411-040941-0411-070941-0411-11DIANEAL PD-2 Peritoneal Dialysis Solution with 2.5% Dextrose1000200030005000600010003000300060006000L5B5173L5B5177L5B5179L5B5194L5B97110941-0413-050941-0413-060941-0413-040941-0413-070941-0413-01DIANEAL PD-2 Peritoneal Dialysis Solution with 4.25% Dextrose1000200030005000600010003000300060006000L5B5183L5B5187L5B5189L5B5195L5B97120941-0415-050941-0415-060941-0415-040941-0415-070941-0415-01DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5%Dextrose20003000500060003000300060006000L5B4825L5B9901L5B4826L5B97700941-0409-060941-0409-050941-0409-070941-0409-01DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose20003000500060003000300060006000L5B9727L5B9902L5B5202L5B97710941-0457-080941-0457-020941-0457-050941-0457-01DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 4.25% Dextrose20003000500060003000300060006000L5B9747L5B9903L5B5203L5B97720941-0459-080941-0459-020941-0459-050941-0459-01Plastic container with blue pull tipDIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose50005000EZPB5245R0941-0484-01DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose50005000EZPB5255R0941-0487-01DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 4.25% Dextrose50005000EZPB5265R0941-0490-01Plastic container with pull ringDIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose60006000VBB4928US0941-0472-01DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose60006000VBB4931US0941-0475-01All DIANEAL peritoneal dialysis solutions have overfills which are declared on container labeling.Freezing of solution may occur at temperatures below 0°C (32°F). Allow to thaw naturally in ambient conditions and thoroughly mix contents by shaking.Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C/77°F): brief exposure up to 40°C (104°F) does not adversely affect the product.Store in moisture barrier overwrap and in carton until ready to use.

17 Patient Counseling Information

Inspection: Advise patients to inspect DIANEAL peritoneal dialysis solutions before use, and not to use if the solution is cloudy, discolored, contains particulate matter or if there is evidence of leakage.Administration: Advise patients on proper administration and the importance of using aseptic technique throughout the entire PD procedure. Advise patients only to use dry heat to warm solution to about 37°C (98°F) and not to microwave or submerge in water.Peritonitis: Advise patients to seek medical attention if they experience signs or symptoms of peritonitis.

Other

Baxter, Ambu-Flex, Dianeal, MiniCap and UltraBag are trademarks of Baxter International Inc.Baxter Healthcare CorporationDeerfield, IL 60015 USAPrinted in USA0719000089

* Please review the disclaimer below.